Cellectis S.A. (CLLS)

NASDAQ: CLLS · IEX Real-Time Price · USD
2.720
-0.110 (-3.89%)
Feb 26, 2024, 3:59 PM EST - Market closed
-3.89%
Market Cap 194.71M
Revenue (ttm) 24.41M
Net Income (ttm) -85.01M
Shares Out 71.58M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,666
Open 2.810
Previous Close 2.830
Day's Range 2.650 - 2.810
52-Week Range 0.963 - 3.774
Beta 3.14
Analysts Strong Buy
Price Target 11.00 (+304.41%)
Earnings Date Mar 6, 2024

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2007
Employees 231
Stock Exchange NASDAQ
Ticker Symbol CLLS
Full Company Profile

Financial Performance

In 2022, Cellectis's revenue was 25.73 million, a decrease of -33.35% compared to the previous year's 38.60 million. Losses were -106.14 million, -7.06% less than in 2021.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CLLS stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 304.41% from the latest price.

Price Target
$11.0
(304.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

5 weeks ago - GlobeNewsWire

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c...

2 months ago - GlobeNewsWire

Cellectis' Shareholders Meeting to be Held on December 22, 2023

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving ...

3 months ago - GlobeNewsWire

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequ...

3 months ago - GlobeNewsWire

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

•  Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I N...

4 months ago - GlobeNewsWire

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...

4 months ago - GlobeNewsWire

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

4 months ago - GlobeNewsWire

Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

The U.S.-listed shares of Cellectis S.A. CLLS rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 m...

Other symbols: AZN
4 months ago - Market Watch

AstraZeneca signs drug development deal with biotech Cellectis

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas incl...

Other symbols: AZN
4 months ago - Reuters

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration Agree...

4 months ago - GlobeNewsWire

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...

4 months ago - GlobeNewsWire

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...

4 months ago - GlobeNewsWire

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

4 months ago - GlobeNewsWire

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...

5 months ago - GlobeNewsWire

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

7 months ago - GlobeNewsWire

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

7 months ago - GlobeNewsWire

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

7 months ago - GlobeNewsWire

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

8 months ago - GlobeNewsWire

Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 27, 2023

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c...

8 months ago - GlobeNewsWire

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

9 months ago - GlobeNewsWire

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

9 months ago - GlobeNewsWire

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

9 months ago - GlobeNewsWire

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

10 months ago - GlobeNewsWire

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

10 months ago - GlobeNewsWire

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population BALLI-01 (evaluating UCART22) abstract demonstrates safety and...

10 months ago - GlobeNewsWire